Skip to the main content

Review article

Endothelins - clinical perspectives

Adriana Unic ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Lovorka Derek ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Natasa Hodak ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Domagoj Marijancevic ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Marina Ceprnja ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Tihana Serdar ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Maja Krhac ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia
Zeljko Romic ; Clinical Department of Laboratory Diagnostics; Dubrava University Hospital, Zagreb, Croatia


Full text: english pdf 197 Kb

page 231-242

downloads: 1.016

cite


Abstract

Endothelins (ET) are a group of endogenous peptides, which have a strong and long-lasting vasocon-strictive effect. Three isoforms of endothelins coded by three different genes have been identified to date. Endothelin-1 (ET-1) is the most potent vasoconstrictive agent currently identified, and it was originally isolated and characterized from the culture media of aortic endothelial cells. Two other iso-forms, named endothelin-2 (ET-2) and endothelin-3 (ET-3), were subsequently identified, along with structural homologues isolated from the venom of Actractapis engaddensis known as the sarafotoxins. The biological effects of endothelin production are determined via activation of one or two G-protein coupled receptors, endothelin receptors A (ETRA) and B (ETRB1 and ETRB2). Recently endothelin receptor C (ETRC) was discovered, however, its functions and distribution still remain unclear. The effects mediated by ET-1 via ETRA are vasoconstriction, bronchoconstriction and secretion of aldosterone. Agonists related to the ETRB1 activation cause vasodilatation by stimu-lating NO, PGI2 and endothelium-derived hyperpolarizing factor (EDHF). In contrast, coupling to ETRB2 causes vasoconstriction. Involvement of ET has been demonstrated in the pathophysiology of certain disorders. In this review, we discuss the physiological and pathophysiological role of endothe-lium-derived ET-1, the pharmacology of its two receptors, focusing on the role of ET-1 in the develo-pment of some pathophysiological conditions.

Keywords

endothelin 1; endothelin receptor; endothelin receptor antagonist; endothelin converting enzyme

Hrčak ID:

72943

URI

https://hrcak.srce.hr/72943

Publication date:

15.10.2011.

Visits: 1.916 *